UNSPSC 51422115: Fluocortin butyl

This classification denotes a dermatologic agent and glucocorticoid C26H35FO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6N7OA9MO7O, chemically known as butyl 6.alpha.-fluoro-11.beta.-hydroxy-16.alpha.-methyl-3,20-dioxopregna-1,4-dien-21-oate, but more generally known as fluocortin butyl, which bears US NIH Compound Identifier 15942715. European Medicines Agency schedules Fluocortin butyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13900MIG.

Most nations, for tariff and trade purposes, schedule fluocortin butyl under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCORTIN BUTYL remains US FDA's Preferred Term for this commodity. SMILES: CCCCOC(=O)C(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2C[C@@H](C4=CC(=O)C=C[C@]34C)F)O)C)C.

UNSPSC 51422115 Fluocortin butyl is a Commodity code that nominally refers to a specific pharmaceutical ingredient, but the recent state and local solicitations tagged under it show minimal alignment with that narrow product scope. The Seminole County, Florida opportunity requests naloxone and drug deactivation systems for community health support, while the Texas Health and Human Services Commission's RFI explores direct-to-manufacturer prescription fulfillment models—neither directly involves fluocortin butyl procurement. State and local governments appear to use this code inconsistently or as a catch-all for certain pharmaceutical or health-related products outside its strict definition.

Activity under this code remains sparse and geographically limited to Florida and Texas in the recent record. Issuing bodies include a county health department (Seminole County) and a state health agency (Texas HHS Commission). The Seminole County IFB for naloxone and drug deactivation systems, posted June 30, 2026, with a response deadline of July 26, 2023, calls for 1,900 units of naloxone and 800 deactivation systems annually through quarterly deliveries, with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas RFI, posted April 3, 2026, is a preliminary market-intelligence solicitation seeking vendor capabilities for direct-to-manufacturer pharmaceutical contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal evaluation timeline or budget specified. Both opportunities require standard federal compliance (E-Verify, drug-free workplace certification, clean air and water pollution control adherence) and insurance coverage documentation. The mismatch between the code's pharmaceutical-ingredient definition and the actual health-systems procurement being tagged suggests that business development professionals should verify code-to-scope alignment with state and local procurement offices before pursuing opportunities listed under this category.